Inclusion Criteria:

          -  Participants greater than or equals to (>=) 18 years of age inclusive at the time of
             signing the informed consent

          -  Participants who have histologically confirmed diagnosis of Stage IV NSCLC:

               1. Participants in Cohort A, B, and C must not have received prior systemic therapy
                  treatment for their Stage IV NSCLC

               2. Participants who had disease progression on previous treatment with Programmed
                  death-ligand 1 (PD- L1) inhibitors in combination with platinum-based
                  chemotherapy are enrolled in Cohort D, as long as therapy was completed at least
                  28 days of the first study intervention.

          -  Have measurable disease based on Response evaluation criteria in solid tumors (RECIST)
             1.1

          -  Have a life expectancy of at least 3 months

          -  Availability of archived tumor material (less than [<] 6 months old) adequate for
             biomarker analysis is mandatory at Screening, central laboratory confirmation is
             required. Fresh biopsies should be collected if archived tumor material is not
             available

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study
             entry and date of first dose

        Exclusion Criteria:

          -  The participant's tumor harbors an epidermal growth factor receptor (EGFR) sensitizing
             (activating) mutation,ROS1 rearrangement, or BRAF V600E mutation or anaplastic
             lymphoma kinase (ALK) positive, if targeted therapy is locally approved

          -  Mixed small cell with NSCLC cancer histology

          -  Has received major surgery within 4 weeks prior to the first dose of study
             intervention; received thoracic radiation therapy (RT) of > 30 gray (Gy) within 6
             months prior to the first dose of study intervention

          -  Previous malignant disease (other than the target malignancy to be investigated in
             this study) within the last 3 years

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Participants with previously treated brain metastases may participate
             provided they are clinically stable for at least 2 weeks after the end of the RT and,
             have no evidence of new or enlarging brain metastases evaluated by imaging, preferably
             brain magnetic resonance imaging (MRI)

          -  Known severe hypersensitivity to study intervention or any components in their
             formulations

          -  For participants in Cohort A, B and C: Has received prior systemic therapy for Stage
             IV NSCLC, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic
             T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)

          -  Unable to tolerate computed tomography (CT) or MRI in the opinion of the Investigator
             and/or allergy to contrast material.